Photo by nci from unsplash
Despite the clinical success of monoclonal and bispecific antibodies, there are still limitations in the therapeutic effect of malignant tumors, such as low response rate, treatment resistance, etc., inspiring the… Click to show full abstract
Despite the clinical success of monoclonal and bispecific antibodies, there are still limitations in the therapeutic effect of malignant tumors, such as low response rate, treatment resistance, etc., inspiring the exploration of trispecific antibodies (TsAbs). TsAbs further improve the safety and efficacy and has great clinical potential through three targets combinations and formats optimization. This article reviews the development history and the target combination features of TsAbs. Although there are still great challenges in the clinical application of TsAbs, it is undeniable that TsAbs may be a breakthrough in the development of antibody drugs. This article is protected by copyright. All rights reserved.
Journal Title: Immunology
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!